Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of MorphoSys's Pelabresib?
Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)....
Pelabresib by MorphoSys for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...
Pelabresib by MorphoSys for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...
Pelabresib by MorphoSys for Myelofibrosis: Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase III for Myelofibrosis. According to GlobalData, Phase III drugs...
Pelabresib by MorphoSys for Essential Thrombocythemia: Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase II for Essential Thrombocythemia. According to GlobalData, Phase II...
Pelabresib by MorphoSys for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According to...